The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence
Key result
2013 ACC/AHA cholesterol guideline could prevent ~450,000 more ASCVD events over 10 years versus earlier guidelines.
Why the study?
Does the 2013 ACC/AHA cholesterol guideline risk-based approach improve the prevention of ASCVD events compared to earlier LDL-C target-based guidelines?
Population
Patients at risk for atherosclerotic cardiovascular disease (ASCVD)
Comparison
2013 ACC/AHA cholesterol guideline risk-based… vs Earlier cholesterol guidelines recommending…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support risk-based statin eligibility over LDL targets; leaves open prospective validation of projected ASCVD reductions.
Key Points
- To evaluate the 2013 ACC/AHA guideline for cholesterol treatment and its impact on atherosclerotic cardiovascular disease risk.
- Analyzed evidence from randomized clinical trials supporting the new risk-based approach.
- Compared the 2013 guidelines with earlier LDL-C treatment thresholds.
- Identified high-risk patients with a higher burden of atherosclerosis.
- The 2013 guideline is projected to prevent up to 450,000 ASCVD events over 10 years.
- Regular monitoring of LDL-C levels is essential for assessing treatment adherence.
- Ezetimibe has shown to effectively lower LDL-C and meet safety standards when added to statin therapy.
Structured PICO
Does the 2013 ACC/AHA cholesterol guideline risk-based approach improve the prevention of ASCVD events compared to earlier LDL-C target-based guidelines?
P
Population
Patients at risk for atherosclerotic cardiovascular disease (ASCVD)
I
Intervention
2013 ACC/AHA cholesterol guideline risk-based approach to statin therapy
C
Comparator
Earlier cholesterol guidelines recommending LDL-C treatment thresholds and targets
O
Outcome
ASCVD eventshard clinical
The 2013 ACC/AHA cholesterol guideline's risk-based approach to statin therapy is projected to prevent up to 450,000 more ASCVD events over 10 years compared to previous LDL-C target-based guidelines.
Cite This Study
Robinson et al. (2015) conducted a review in Atherosclerotic cardiovascular disease risk. 2013 ACC/AHA cholesterol guideline vs. Earlier cholesterol guidelines was evaluated on Atherosclerotic cardiovascular disease (ASCVD) events. The 2013 ACC/AHA cholesterol guideline's risk-based approach better identifies high-risk patients and could prevent up to 450,000 more ASCVD events over 10 years compared to earlier guidelines.